



November 8, 2011

Tekmira Provides Corporate Update and Announces Third Quarter 2011 Results

Conference Call at 4:30 pm Eastern Time Today

VANCOUVER, British Columbia, Nov. 8, 2011 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced its financial and operational results for the third quarter ended September 30, 2011.

"Over the past quarter, we have focused on our core business and made progress with the expanded clinical development of TKM-PLK1 and advancement of TKM-Ebola towards a Phase 1 clinical trial. Our lipid nanoparticle delivery technology continues to lead the RNAi field by supporting multiple clinical candidates from Tekmira and our partners. The next few quarters represent an exciting time for the RNAi field when we will see multiple clinical data points from our TKM-PLK1 product and other products enabled by our technology, including Alnylam's ALN-TTR and ALN-PCS product candidates," said Dr. Mark J. Murray, Tekmira's President and CEO.

Corporate Update and Third Quarter Highlights

- A Phase 1 human clinical trial for TKM-PLK1 is ongoing. TKM-PLK1 targets polo-like kinase 1, or PLK1, a cell cycle protein involved in tumor cell proliferation and a validated oncology target. In December 2010, Tekmira initiated a TKM-PLK1 Phase 1 clinical trial, which is being conducted at three medical centers in the United States. The trial is an open label, multi-dose, multi-cycle, dose-escalation study designed to evaluate the safety, tolerability and pharmacokinetics of TKM-PLK1 and determine the maximum tolerated dose in patients with advanced solid tumors.

This past quarter, Tekmira received approval from the United States Food and Drug Administration (FDA) to proceed with a new Phase 1 clinical trial for TKM-PLK1 in collaboration with its partners at the United States National Cancer Institute (NCI) and patient enrollment has commenced. This clinical trial will employ a route of administration of TKM-PLK1 directly into the liver via Hepatic Artery Infusion (HAI) in patients with liver metastases. This allows for direct measurement of tumor delivery, PLK1 knockdown, and RNAi activity in tumor biopsies.

- Tekmira continues to develop its TKM-Ebola product under a US\$140 million contract awarded by the U.S. Government's Transformational Medical Technologies (TMT) Program. The TMT contract will support the development of TKM-Ebola through FDA approval. TKM-Ebola is on track for approval of an investigational new drug (IND) application in the second half of 2011 and initiation of a Phase 1 human clinical trial in the first quarter of 2012. Tekmira's work on the TKM-Ebola program also supports continued lipid nanoparticle (LNP) technology innovations around process development, manufacturing scale-up, and lyophilization.
- Tekmira, along with collaborators at SomaGenics, Inc. and Roche, presented data demonstrating — for the first time — *in vivo* efficacy of RNAi against the Hepatitis C virus (HCV). The data was presented at the 7th Annual Meeting of the Oligonucleotide Therapeutics Society (OTS) held September 8-10, 2011 in Copenhagen, Denmark.
- In August 2011, Tekmira obtained an exclusive, worldwide license to a novel and proprietary RNAi technology called MV-RNA (multivalent RNA) from Halo-Bio RNAi Therapeutics, Inc. (Halo-Bio). Halo-Bio's MV-RNA technology comprises single macromolecules capable of mediating RNAi at multiple unique target sites. MV-RNA can target three sites on a single gene or up to three separate genes simultaneously. Tekmira has successfully demonstrated multi-gene knockdown using MV-RNA enabled by proprietary LNP formulations.
- Tekmira's LNP technology is enabling the systemic RNAi product pipeline of Alnylam Pharmaceuticals, Inc. Tekmira continues to be the exclusive manufacturer of any LNP-based drug products required by Alnylam through to the end of Phase 2 clinical trials, including the products ALN-VSP, ALN-TTR and ALN-PCS. Alnylam provided the following guidance within its third quarter 2011 financial results:
 - In August, Alnylam reported that they had completed treatment of patients in the Phase 1 study protocol for ALN-VSP, with some patients continuing treatment in the extension study. As of November, three patients with disease control continue to receive ALN-VSP under the extension protocol, including one endometrial cancer patient with an ongoing partial response who has now received drug for more than 17 months. ALN-

VSP is a LNP-delivered RNAi therapeutic for the treatment of advanced solid tumors with liver involvement.

- ALN-TTR01 is currently enrolling patients in a blinded, randomized, placebo-controlled, single dose escalation Phase 1 clinical trial. Alnylam expects to present Phase 1 data later this month at the International Symposium on Familial Amyloidotic Polyneuropathy being held November 20 - 22, 2011 in Kumamoto, Japan.
- Alnylam has now initiated dosing in a Phase 1 trial with ALN-PCS targeting PCSK9 for the treatment of severe hypercholesterolemia. The trial is being conducted in the UK as a randomized, placebo-controlled, single-ascending dose study enrolling approximately 32 healthy voluntary subjects with elevated baseline LDL cholesterol. More detail and additional information about Alnylam's programs can be found at <http://www.alnylam.com>.
- Subsequent to quarter end, Tekmira provided a periodic update to the ongoing litigation with Alnylam and AICana Technologies, Inc. Documents related to this lawsuit can be found on the Tekmira website at: www.tekmirapharm.com.
- In October 2011, Tekmira updated its financial guidance. Based on continued strong revenue from its collaboration partners as well as prudent management of its expenses, Tekmira now believes that its current funds on hand plus expected revenue will extend its cash runway to the end of 2012. This projection includes continued investment in the advancement of Tekmira's product candidates and its lipid nanoparticle technology as well as the conclusion of the ongoing Alnylam / AICana litigation.

Financial results

Net Loss

For the first nine months of 2011, net loss was \$8.1 million (\$0.73 per common share) as compared to a net loss of \$10.6 million (\$1.02 per common share) for the first nine months of 2010. For Q3 2011, net loss was \$1.5 million (\$0.12 per common share) as compared to a net loss of \$2.4 million (\$0.24 per common share) for Q3 2010.

In general, losses have decreased with new revenue from the TKM-Ebola contract that started in July 2010. Revenue is a mix of compensation for staff time and overheads and reimbursement for research and development costs.

Revenue

Revenue was \$4.2 million for Q3 2011 as compared to \$10.4 million in Q3 2010.

In Q3 2010, Tekmira received a \$5.9 million license amendment payment from Talon Therapeutics, Inc. (formerly Hana Biosciences, Inc.). The \$5.9 million was then paid to certain contingent creditors in full settlement of a contingent obligation and therefore was also included as a "loss on the purchase and settlement of exchangeable and development notes" in Tekmira's Q3 2010 income statement expenses. Talon is developing targeted chemotherapy products under a legacy license agreement from Tekmira entered into in May 2006. Following the license amendment, Tekmira is eligible to receive milestone payments from Talon of up to US\$19.0 million upon achievement of further development and regulatory milestones and is also eligible to royalties on product sales.

On July 14, 2010, Tekmira signed a contract with the United States Government to advance an RNAi therapeutic utilizing Tekmira's LNP technology to treat Ebola virus infection. Under the contract, Tekmira is being reimbursed for costs incurred, including an allocation of overheads, and is being paid an incentive fee. Tekmira recorded \$2.0 million in revenue from this contract in Q3 2011.

Alnylam contract revenue was \$1.4 million in Q3 2011 and \$1.8 million in Q3 2010. Under an Alnylam Manufacturing Agreement there is a contractual minimum payment for the provision of staff in each of the three years from 2009 to 2011 and Alnylam is reimbursing Tekmira for any external costs incurred. Tekmira also recorded \$0.5 million in milestone revenue in Q3 2011 when Alnylam initiated a Phase 1 human clinical trial for ALN-PCS. ALN-PCS is manufactured by Tekmira and is enabled by Tekmira's LNP delivery technology.

Research, development, collaborations and contracts expenses

Research, development, collaborations and contracts expenses were \$4.4 million in Q3 2011 as compared to \$5.2 million in Q3 2010. In Q3 2010 Tekmira incurred more costs related to batch manufacture for Alnylam than in Q3 2011. Also, in Q3 2010 Tekmira paid out staff bonuses following the award of the TKM-Ebola contract. No bonuses have been paid in 2011.

General and administrative

General and administrative expenses were \$1.2 million in Q3 2011 as compared to \$1.5 million in Q3 2010. Q3 2010 general and administrative expenses were higher than usual as they included costs related to Tekmira's NASDAQ share listing.

2011 financial guidance

At September 30, 2011, Tekmira had cash and cash equivalents of approximately \$9.2 million as compared to \$12.3 million at December 31, 2010. In Q2 2011, Tekmira completed an equity offering, raising gross proceeds of \$5.1 million. Following the financing, Tekmira now believes that its current funds on hand plus expected income, including funds from collaborative partners and the U.S. Government, will be sufficient to continue product development until the end of 2012.

Conference Call Information

Tekmira will hold a conference call and webcast on Tuesday, November 8, 2011 at 1:30 pm Pacific Time (4:30 pm Eastern Time) to discuss its third quarter operating results and a summary of corporate highlights. To access the conference call, please dial 914-495-8556 or 1-800-585-8367 and reference conference ID 20403984. The live webcast can be accessed through the Investor section of Tekmira's website at www.tekmirapharm.com.

An archived webcast will be available on the Tekmira website approximately two hours after the event. In addition, a replay of the conference call will be available until November 15, 2011 by calling 404-537-3406 or 1-855-859-2056 and referencing conference ID 20403984.

About RNAi and Tekmira's LNP Technology

RNAi therapeutics have the potential to treat a broad number of human diseases by "silencing" disease causing genes. The discoverers of RNAi, a gene silencing mechanism used by all cells, were awarded the 2006 Nobel Prize for Physiology or Medicine. RNAi therapeutics, such as "siRNAs," require delivery technology to be effective systemically. LNP technology is one of the most widely used siRNA delivery approaches for systemic administration. Tekmira's LNP technology (formerly referred to as stable nucleic acid-lipid particles or SNALP) encapsulates siRNAs with high efficiency in uniform lipid nanoparticles which are effective in delivering RNAi therapeutics to disease sites in numerous preclinical models. Tekmira's LNP formulations are manufactured by a proprietary method which is robust, scalable and highly reproducible and LNP-based products have been reviewed by multiple FDA divisions for use in clinical trials. LNP formulations comprise several lipid components that can be adjusted to suit the specific application.

About Tekmira

Tekmira Pharmaceuticals Corporation is a biopharmaceutical company focused on advancing novel RNAi therapeutics and providing its leading lipid nanoparticle delivery technology to pharmaceutical partners. Tekmira has been working in the field of nucleic acid delivery for over a decade and has broad intellectual property covering LNPs. Further information about Tekmira can be found at www.tekmirapharm.com. Tekmira is based in Vancouver, B.C.

The Tekmira Pharmaceuticals logo is available at <http://www.globenewswire.com/newsroom/prs/?pkgid=8319>

Forward-Looking Statements and Information

This news release contains "forward-looking statements" or "forward-looking information" within the meaning of applicable securities laws (collectively, "forward-looking statements"). Forward-looking statements are generally identifiable by use of the words "believes," "may," "plans," "will," "anticipates," "intends," "budgets," "could," "estimates," "expects," "forecasts," "projects," and similar expressions, and the negative of such expressions. Forward-looking statements in this news release include statements about Tekmira's strategy, future operations, clinical trials, prospects and the plans of management; RNAi (ribonucleic acid interference) product development programs; estimates of the number of clinical development programs to be undertaken by Tekmira and its product development partners; selection of additional product candidates; timing of release of clinical data — including the ALN-TTR data to be released in November 2011 in Japan; the quantum and timing of potential funding; use of lipid nanoparticle (LNP) technology by Tekmira's licensees; the effects of Tekmira's products on the treatment of cancer and infectious disease; Tekmira's expectations with respect to existing and future agreements with third parties; statements about the approval of an IND for TKM-Ebola and initiation of a Phase 1 human clinical trial; statements about the nature, prospects and anticipated timing to resolve the complaint filed by Tekmira against Alnylam and AICana; the nature, scope and quantum of damages sought by Tekmira from Alnylam and AICana; measures taken to ensure that Tekmira can pursue the litigation with Alnylam and AICana without interruption to Tekmira's core business activities; estimates and scope of Tekmira's financial guidance and expected cash runway in light of the litigation with Alnylam and AICana; and estimates of the length of time Tekmira's business will be funded by its anticipated financial resources.

With respect to the forward-looking statements contained in this news release, Tekmira has made numerous assumptions

regarding, among other things: LNP's status as a leading RNAi delivery technology; the effectiveness of Tekmira's products as a treatment for cancer and infectious disease; the developmental milestones and approvals required to trigger funding for TKM-Ebola from the Transformational Medical Technologies program; Tekmira's research and development capabilities and resources; U.S. Food and Drug Administration (FDA) approval with respect to commencing clinical trials; the timing and obtaining of regulatory approvals for Tekmira's products; the timing and results of clinical data releases — including the ALN-TTR data expected to be released in Japan in November 2011 — and the use of LNP technology by Tekmira's development partners and licensees; the time required to complete research and product development activities; the timing and quantum of payments to be received under contracts with Tekmira's collaborative partners including the U.S. Government and the manufacturing agreement with Alnylam; the nature and prospects of the litigation with Alnylam and AICana; based on the conduct of Alnylam and AICana, the nature, scope and quantum of damages that Tekmira is entitled to; costs and timing of the litigation with Alnylam and AICana and the effects of such on Tekmira's financial position and execution of Tekmira's business strategy; the effect of Alnylam's and AICana's answers and counterclaims on Tekmira's litigation position; the sufficiency of budgeted capital expenditures in carrying out planned activities; Tekmira's ability to protect its intellectual property rights and not to infringe on the intellectual property rights of others; the ability to succeed at establishing a successful commercialization program for any of Tekmira's products; and the availability and cost of labour and services. While Tekmira considers these assumptions to be reasonable, these assumptions are inherently subject to significant business, economic, competitive, market and social uncertainties and contingencies.

Additionally, there are known and unknown risk factors which could cause Tekmira's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements contained herein. Known risk factors include, among others: the possibility that other organizations have made advancements in RNAi delivery technology that Tekmira is not aware of; the FDA will not approve the commencement of Tekmira's planned clinical trials or approve the use of Tekmira's products and generally, difficulties or delays in the progress, timing and results of clinical trials; the FDA may determine that the design and planned analysis of Tekmira's clinical trials do not adequately address the trial objectives in support of Tekmira's regulatory submissions; future operating results are uncertain and likely to fluctuate; competition from other pharmaceutical or biotechnology companies; Tekmira's ability to raise additional financing required to fund further research and development, clinical studies, and obtain regulatory approvals, on commercially acceptable terms or at all; economic and capital market conditions; Tekmira's ability to obtain and protect intellectual property rights, and operate without infringing on the intellectual property rights of others; Tekmira's research and development capabilities and resources will not meet current or expected demand; Tekmira's development partners and licensees conducting clinical trial and development programs will not result in expected results on a timely basis, or at all; anticipated payments under contracts with Tekmira's collaborative partners including the U.S. Government and Alnylam will not be received by Tekmira on a timely basis, or at all, or in the quantum expected by Tekmira; the U.S. Government may reduce or cancel certain defense spending, including Tekmira's contract to develop TKM-Ebola; approval of an IND for TKM-Ebola may not be obtained when anticipated or at all; initiation of a Phase 1 human clinical trial for TKM-Ebola may not occur when anticipated or at all; pre-clinical trials may not be completed, or clinical trials started, when anticipated or at all; pre-clinical and clinical trials may be more costly or take longer to complete than anticipated; pre-clinical or clinical trials may not generate results that warrant future development of the tested drug candidate; Tekmira may become subject to product liability or other legal claims for which the Company has made no accrual in its financial statements; the final outcome of the litigation with Alnylam and AICana is not presently determinable or estimable and may result in an outcome that is unfavorable to Tekmira, including damages and other relief against Tekmira claimed by Alnylam and AICana in their counterclaims; there may be no basis for which Tekmira has any rights or entitlement to damages from Alnylam or AICana in the quantum anticipated by Tekmira, or at all; legal expenses associated with litigation are uncertain and may exceed current estimates, which may have a material adverse effect on Tekmira's financial position and ongoing business strategy; the uncertainty of litigation, including the time and expenses associated therewith; risks and uncertainties involved in the litigation process, such as discovery of new evidence or acceptance of unanticipated or novel legal theories, changes in interpretation of the law due to decisions in other cases, the inherent difficulty in predicting the decisions of judges and juries and the possibility of appeals; Tekmira has not sufficiently budgeted for capital expenditures necessary to carry out planned activities.

A more complete discussion of the risks and uncertainties facing Tekmira appears in Tekmira's Annual Information Form dated March 30, 2011 and available at www.sedar.com or at www.sec.gov/edgar. All forward-looking statements herein are qualified in their entirety by this cautionary statement, and Tekmira disclaims any obligation to revise or update any such forward-looking statements or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments, except as required by law.

CONTACT: Investors

Jodi Regts

Director, Investor Relations

Phone: 604-419-3234

Email: jregts@tekmirapharm.com

Media

David Ryan

Longview Communications Inc.

Phone: 416-649-8007

Email: dryan@longviewcomms.ca